[
  {
    "ts": "2025-12-18T13:30:00+00:00",
    "headline": "Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance",
    "summary": "FOSTER CITY, Calif., December 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day.",
    "url": "https://finance.yahoo.com/news/gilead-sciences-appoints-keeley-wettan-133000058.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "76056361-6f74-3726-8dec-42e107daad79",
      "content": {
        "id": "76056361-6f74-3726-8dec-42e107daad79",
        "contentType": "STORY",
        "title": "Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance",
        "description": "",
        "summary": "FOSTER CITY, Calif., December 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day.",
        "pubDate": "2025-12-18T13:30:00Z",
        "displayTime": "2025-12-18T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/40d133c38fa105da95c034493608ba6a",
          "originalWidth": 480,
          "originalHeight": 320,
          "caption": "Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YImYG5fp2_CGM64I5TdVwA--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/40d133c38fa105da95c034493608ba6a.cf.webp",
              "width": 480,
              "height": 320,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LEULrS2vgcgyh1jSJqZuGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/40d133c38fa105da95c034493608ba6a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-appoints-keeley-wettan-133000058.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-appoints-keeley-wettan-133000058.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T04:24:55+00:00",
    "headline": "Gilead Sciences (GILD) Valuation After Positive Phase 3 Data for Its Bictegravir–Lenacapavir HIV Regimen",
    "summary": "Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens the longer term HIV pipeline story. See our latest analysis for Gilead Sciences. The stock has cooled a little in the last month, with a 30 day share price return of minus 4.6 percent. That still sits within a strong 32.1 percent year to date share price gain and a 5 year total shareholder return...",
    "url": "https://finance.yahoo.com/news/gilead-sciences-gild-valuation-positive-042455029.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "fbe24cdc-6f4a-389a-8b1d-76cc623a2cb6",
      "content": {
        "id": "fbe24cdc-6f4a-389a-8b1d-76cc623a2cb6",
        "contentType": "STORY",
        "title": "Gilead Sciences (GILD) Valuation After Positive Phase 3 Data for Its Bictegravir–Lenacapavir HIV Regimen",
        "description": "",
        "summary": "Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens the longer term HIV pipeline story. See our latest analysis for Gilead Sciences. The stock has cooled a little in the last month, with a 30 day share price return of minus 4.6 percent. That still sits within a strong 32.1 percent year to date share price gain and a 5 year total shareholder return...",
        "pubDate": "2025-12-18T04:24:55Z",
        "displayTime": "2025-12-18T04:24:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-valuation-positive-042455029.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-valuation-positive-042455029.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-18T02:12:53+00:00",
    "headline": "Does Gilead Still Offer Value After Its 2025 Surge and Pipeline Progress?",
    "summary": "Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with the underlying value. Gilead is flat over the last week and down 2.2% over the past month, but the stock is still up 32.1% year to date and 37.6% over the last year, with gains of 58.2% in 3 years and 156.3% in 5 years. Behind these moves, investors have been reacting to a steady stream of...",
    "url": "https://finance.yahoo.com/news/does-gilead-still-offer-value-021253070.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c5a4e54d-0cda-34f7-93e0-5abeb0b1851a",
      "content": {
        "id": "c5a4e54d-0cda-34f7-93e0-5abeb0b1851a",
        "contentType": "STORY",
        "title": "Does Gilead Still Offer Value After Its 2025 Surge and Pipeline Progress?",
        "description": "",
        "summary": "Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with the underlying value. Gilead is flat over the last week and down 2.2% over the past month, but the stock is still up 32.1% year to date and 37.6% over the last year, with gains of 58.2% in 3 years and 156.3% in 5 years. Behind these moves, investors have been reacting to a steady stream of...",
        "pubDate": "2025-12-18T02:12:53Z",
        "displayTime": "2025-12-18T02:12:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-gilead-still-offer-value-021253070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-gilead-still-offer-value-021253070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]